J. Safra Sarasin Holding AG Lowers Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

J. Safra Sarasin Holding AG cut its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 2.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 802,197 shares of the biopharmaceutical company’s stock after selling 20,537 shares during the quarter. Gilead Sciences accounts for 1.3% of J. Safra Sarasin Holding AG’s holdings, making the stock its 18th largest holding. J. Safra Sarasin Holding AG’s holdings in Gilead Sciences were worth $74,099,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of GILD. HHM Wealth Advisors LLC grew its holdings in shares of Gilead Sciences by 118.5% in the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 154 shares in the last quarter. YANKCOM Partnership acquired a new position in Gilead Sciences during the 4th quarter worth $28,000. Decker Retirement Planning Inc. acquired a new position in shares of Gilead Sciences during the fourth quarter worth about $29,000. Crews Bank & Trust acquired a new stake in Gilead Sciences in the fourth quarter valued at approximately $31,000. Finally, Stephens Consulting LLC increased its position in shares of Gilead Sciences by 325.0% in the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 260 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analyst Upgrades and Downgrades

GILD has been the topic of a number of analyst reports. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a research note on Wednesday, February 12th. BMO Capital Markets increased their price target on shares of Gilead Sciences from $110.00 to $115.00 and gave the company an “outperform” rating in a research note on Wednesday, February 12th. Piper Sandler upped their target price on shares of Gilead Sciences from $105.00 to $110.00 and gave the company an “overweight” rating in a report on Wednesday, February 12th. DZ Bank upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 price objective for the company in a research note on Thursday, February 13th. Finally, Morgan Stanley upped their target price on Gilead Sciences from $123.00 to $130.00 and gave the company an “overweight” rating in a research report on Tuesday, March 11th. Eleven research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $105.12.

Gilead Sciences Stock Down 0.4 %

GILD stock opened at $104.49 on Monday. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. The company’s 50-day moving average price is $109.16 and its 200 day moving average price is $97.63. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $119.96. The company has a market cap of $130.10 billion, a P/E ratio of 282.40, a P/E/G ratio of 0.71 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. On average, research analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, March 28th. Stockholders of record on Friday, March 14th were given a $0.79 dividend. The ex-dividend date was Friday, March 14th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 3.02%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. Gilead Sciences’s dividend payout ratio (DPR) is currently 854.05%.

Insider Transactions at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, April 15th. The stock was sold at an average price of $106.40, for a total transaction of $266,000.00. Following the completion of the transaction, the chief financial officer now directly owns 168,174 shares in the company, valued at $17,893,713.60. The trade was a 1.46 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders sold 302,785 shares of company stock valued at $30,540,875 in the last 90 days. 0.27% of the stock is currently owned by insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.